SOYBEAN PLANT NAMED 'G13LL-44'
    61.
    发明申请

    公开(公告)号:US20200296915A1

    公开(公告)日:2020-09-24

    申请号:US16359690

    申请日:2019-03-20

    IPC分类号: A01H6/54 A01H5/10

    摘要: Herein provided is a new soybean variety designated ‘G13LL-44’ as well as the seeds, plants and derivatives of the new soybean variety ‘G13LL-44’. Also provided are tissue cultures of the new soybean variety ‘G13LL-44’ and the plants regenerated therefrom. Methods for producing soybean plants by crossing the new soybean variety ‘G13LL-44’ with itself or another soybean variety and plants produced by such methods are also provided. ‘G13LL-44’ is a MG VII line with glufosinate tolerance technology, and with resistance to race 3 of the soybean cyst nematode and frogeye leaf spot, and moderate resistance to southern root-knot nematode. ‘G13LL-44’ yielded 1.4 bu/ac (2.3%) greater than its recurrent parent ‘G00-3213’, across 11 environments and 0.5 bu/ac more than the high-yielding check cultivar ‘AG738 RR’. ‘G13LL-44’ provides a high yielding glufosinate tolerant soybean cultivar with superior nematode resistance.

    Metal-encapsulated carbonaceous dots

    公开(公告)号:US10548993B2

    公开(公告)日:2020-02-04

    申请号:US15500691

    申请日:2015-07-30

    摘要: Nanoparticles described as metal-encapsulated carbonaceous dots or M@C-dots are disclosed. Also disclosed are specific M@C-dots with gadolinium, so called Gd@C-dots. These nanoparticles are biologically inert and preclude the release of metal in biological environments. In addition, despite a dimension exceeding the commonly recognized threshold for renal clearance, the disclosed nanoparticles can be efficiently cleared via urine after systematic injection. Methods of making and using such nanoparticles are also disclosed.

    Systems and methods for measuring mitochondrial capacity

    公开(公告)号:US10542932B2

    公开(公告)日:2020-01-28

    申请号:US15616318

    申请日:2017-06-07

    摘要: In one embodiment, measuring mitochondrial capacity includes performing arterial occlusions on a patient, measuring oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin within the patient's body during the occlusions, calculating a blood volume correction factor that accounts for a change in blood volume that occurs during the arterial occlusions, and applying the correction factor to the measured oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin measurements to obtain correct oxygenated hemoglobin/myoglobin and deoxygenated hemoglobin/myoglobin measurements.